# Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer

> **NCT03937895** · PHASE1,PHASE2 · COMPLETED · sponsor: **SMT bio Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **BIOLOGICAL:** 'SMT-NK' Inj (allogeneic Natural Killer cell)
- **DRUG:** Pembrolizumab Injection [Keytruda]

## Key facts

- **NCT ID:** NCT03937895
- **Lead sponsor:** SMT bio Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-03
- **Primary completion:** 2021-06-08
- **Final completion:** 2021-06-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03937895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03937895, "Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03937895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*